Preparation method and application of etogestrel intermediate
The new synthesis process for etonogestrel intermediates using 11α,17β-dihydroxy-18-methylestrone-4-ene-3-one as a starting material simplifies the production of 3,3-ethylenedioxy-13-ethyl-11-methylene-5-estren-17-one, overcoming safety hazards and cost issues in existing methods, suitable for industrial application.
Patent Information
- Application Number
- CN202411201558.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-29
- Publication Date
- 2024-12-06
AI Technical Summary
Current synthesis methods for etonogestrel intermediates face challenges such as long reaction times, low conversion rates, complex reaction pathways, safety hazards, and high production costs, particularly due to the use of selective reactions and hazardous reagents, which complicate industrial application.
A new synthesis process using commercially available 11α,17β-dihydroxy-18-methylestrone-4-ene-3-one as a starting material, involving selective protection, oxidation, ketalization, Wittig reaction, and oxidation to produce 3,3-ethylenedioxy-13-ethyl-11-methylene-5-estren-17-one, avoiding hazardous reagents and simplifying the process.
The method provides a cost-effective, safe, and efficient route with high overall yield, suitable for industrial production, addressing the limitations of previous methods by using readily available raw materials and mild reaction conditions.
Smart Images

Figure SMS_1 
Figure SMS_2 
Figure SMS_3
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of pharmaceutical chemistry, and specifically relates to a preparation method and application of an etonogestrel intermediate. Background Art
[0002] Etonogestrel is a multi-dose contraceptive developed by Organon. On October 3, 2001, the FDA approved the contraceptive vaginal ring NuvaRing, whose active ingredients include etonogestrel and ethinyl estradiol (etonogestrel 11.7 mg; ethinyl estradiol 2.7 mg). Immediately thereafter, Organon developed a new subcutaneous implant formulation of etonogestrel, which was approved by the FDA for marketing on July 17, 2006. Each etonogestrel contains 68 mg, and the three-year contraceptive efficacy is over 99.5%. The operation process is simple, safe and reliable. Its contraceptive mechanism is: etonogestrel binds to the cytoplasmic progesterone receptor in the reproductive system, and then activates progesterone receptor-mediated gene expression. Due to the negative feedback mechanism, the release of luteinizing hormone (LH) is inhibited, resulting in the inhibition of ovulation. The changes in cervical mucus and endometrium only achieve the purpose of contraception by changing the concentration of the hormone in the female body, inhibiting ovulation, and creating an environment in the uterus that is not suitable for pregnancy. It also has a smaller impact on estradiol in the female body and can also alleviate the problem of dysmenorrhea in women. This variety has broad market prospects. The structure of etonogestrel is shown in the figure below:
[0003]
[0004] There are many reports in the literature on the preparation methods of etonogestrel and its core intermediates. Hongwu Gao et al. reported a synthesis method of an important intermediate of etonogestrel in 1997 (Synthetic Communications 27(11):1981-1987; Synthetic Communications 29(5):572-576). The reported synthesis route is as follows:
[0005] The hydrolyzate is used as a raw material, and 11-alpha hydroxydiketone is generated by fermentation with Aspergillus ochraceus, and then the diketal is obtained by protecting the carbonyl groups at positions 3 and 17 under ethylene glycol ketal, and then the 11-methylene diketal is obtained by Wittig reaction, and finally the core intermediate 11-methylene diketal is obtained by hydrolysis. When constructing 3,17 diketal in the third step of this synthetic route, the reaction time is long and the conversion rate is not high. Most of it stays at the 3-position monoketal protection, and there are few products protected by 3,17-diketal. Increasing the reaction temperature will lead to more complicated reactions. In addition, the intermediate still needs to protect the 3-position carbonyl group in the subsequent preparation of API, which leads to a long overall route, many side reactions, and great difficulty in industrialization.
[0006]
[0007] The Italian company Industriale Chimica reported its synthetic route in patent US9422326B2: using 11-hydroxydiketone as the starting material, oxidizing the 11-hydroxyl group to obtain triketone, and then selectively protecting the 3-ketal to obtain the 3-ketal, and then selectively reducing the 17-carbonyl group by NaBH4 in the presence of CeCl3 to obtain the 17-hydroxy-3-ketal structure, and then constructing the 11-methylene group by Wittig reaction, and finally using IBX oxidation to obtain the target intermediate. Among the five steps of this method, two steps involve selective reactions. One is the selective ketal protection in the second step, which requires selectively protecting only the 3-carbonyl group among the 3-, 17-, and 11-carbonyl groups. Although it is well known that the three carbonyl steroids have steric hindrances of 11>17>3, and the reaction activity is 3>17>11, it is inevitable that multi-protected impurities will be generated during the reaction. These impurities are transferred to subsequent reactions, which puts pressure on the quality of the API. The second is the selective reduction of the carbonyl group at position 17, which involves the controlled material sodium borohydride. The reaction process and post-processing will produce hydrogen, which poses a high production safety hazard. 3. The oxidation reaction of the 11-hydroxyl group in the Py / DMSO system will produce a foul odor and a low odor threshold by-product dimethyl sulfide, which will put pressure on the EHS produced. Therefore, this process also has defects in industrial application.
[0008]
[0009] Hunan Keyi New Biology uses triketone as the starting material in the synthetic route reported in its patent CN117126221A. The 3- and 17-positions are simultaneously reduced to alcohol to obtain 11-ketodiol, followed by the Wittig reaction to construct the 11-position methylene group, and finally the 3- and 17-hydroxy groups are reoxidized to obtain the etonogestrel core intermediate 11-methylenedione. On the one hand, this method also involves the controlled reagent sodium borohydride in the reduction step, which has a high production safety risk. On the other hand, α,β-hydroxy isomers at the 3- and 17-positions will be produced during the reduction process. The presence of these isomers has a negative effect on the separation and purification of the intermediates, as well as the quality and yield. In addition, in the subsequent preparation of APIs, the intermediate also needs the malodorous, low odor threshold auxiliary material ethanedithiol to protect the 3-position carbonyl group, which limits the practical application of this route to a certain extent.
[0010]
[0011] Patent document WO2013 / 071210 uses a more advanced intermediate: ethyl reductant ((13R, 17S)-ethylsecol) as the starting material, oxidizes the hydroxyl group at position 17, delocalizes the double bond to positions 9 and 11 under acidic conditions, then protects the carbonyl group at position 17 with neopentyl glycol, constructs the α-hydroxyl group at position 11 through borohydride-oxidation, and then oxidizes the 11th position, and trimethylsilylmethyl lithium attacks the 11-ketone to obtain the tertiary alcohol protected at position 11, and finally undergoes Birch reduction and hydrolysis under acidic conditions to obtain the core intermediate 11-methylenedione. This route is characterized by a fully chemical synthesis reaction, without a fermentation step for the hydroxyl group at position 11, and constructs the methylene group at position 11 by adding trimethylsilylmethyl lithium to the 11th position and then eliminating it, but the route is relatively long, the yield of the multi-step reaction is about 60%, and the total yield is low.
[0012]
[0013] BIONICE, SLU company published a route for synthesizing etonogestrel in its patent WO2017149091A1, which uses commercially available 11-hydroxydione as the starting material, and obtains the tertiary alcohol at the 11th position through oxidation, 3-position enol ether protection, and trimethylsilylmethyllithium attacking the 11-carbonyl group, and finally obtains etonogestrel through 17-acetylation and hydrolysis. The starting materials of this synthetic route are easy to obtain, and the synthetic steps are short, but the disadvantage is that it also involves the selectivity of the 11th and 17th carbonyl groups in the attack of nucleophilic reagents. In addition, the auxiliary material trimethylsilylmethyllithium for constructing the 11th methyl group is expensive, and the product purification is complicated, which is not conducive to industrial production.
[0014]
[0015] According to the above literature, the current synthesis of etonogestrel is mainly through the core intermediate 11-methylenedione or the core intermediate 3,3-ethylenedioxy-13-ethyl-11-methylene-5-estren-17-one. Among them, 11-methylenedione needs to protect the 3-position ketocarbonyl in the subsequent synthesis of etonogestrel API. During the protection process, due to the presence of 4,5-double bond and 17-ketocarbonyl, double bond displacement and selective protection of ketocarbonyl will lead to quality and yield pressure. In comparison, 3,3-ethylenedioxy-13-ethyl-11-methylene-5-estren-17-one is used as an intermediate. Since the 3-position has been protected, only the 17-position carbonyl acetylation and hydrolysis are required to complete the preparation of etonogestrel API. The complexity of quality research is relatively low and the synthesis efficiency is relatively high. Therefore, the in-depth development of the synthesis method of 3,3-ethylenedioxy-13-ethyl-11-methylene-5-estren-17-one is of great significance to etonogestrel API. Summary of the invention
[0016] In order to solve the shortcomings of the prior art, combined with the great significance of the intermediate for synthesizing the above-mentioned etonogestrel raw material drug: 3,3-ethylenedioxy-13-ethyl-11-methylene-5-estren-17-one and the very limited existing synthesis methods, the purpose of the present invention is to provide a new synthesis process of the etonogestrel intermediate 3,3-ethylenedioxy-13-ethyl-11-methylene-gon-4-en-17-one (3,3-Ethylenedioxy-13-ethyl-11-methylene-gon-4-en-17-one), the synthesis route is simple, the operation is convenient, the equipment requirements are not high, and large-scale production can be achieved, which provides an excellent method selection for synthesizing this important intermediate of etonogestrel.
[0017] In order to achieve the above purpose, after literature review and supplier research, it was found that the synthesis of 11α,17β-dihydroxy-18-methylestrone-4-ene-3-one was reported as early as the British patent (US40189164) in 1965, and there are currently multiple commercial suppliers in the market that can supply this compound. Therefore, the present invention uses the cheap and easily available 11α,17β-dihydroxy-18-methylestrone-4-ene-3-one as a raw material to provide a new and efficient synthesis method of an important intermediate of etonogestrel: 3,3-ethylenedioxy-13-ethyl-11-methylene-4-estrone-17-one.
[0018] The present invention provides a method for preparing an etonogestrel intermediate, which uses a commercially available compound 11α,17β-dihydroxy-18-methylestr-4-ene-3-one shown in formula I as a starting material, and obtains the important etonogestrel intermediate, i.e., the compound 3,3-ethylenedioxy-13-ethyl-11-methylene-5-estrene-17-one shown in formula VI, through selective protection, oxidation reaction, protection, Wittig reaction, and oxidation reaction. The reaction process of the preparation method is shown in reaction formula (I):
[0019]
[0020] Wherein, R is selected from benzoyl, 2-substituted benzoyl, 2,6-disubstituted benzoyl, alkanoyl, that is, the structure of R is shown in the following formula: The substituent R' is selected from H, alkyl, halogen (Cl, Br, I).
[0021] In the present invention, the preparation method comprises the following steps:
[0022] Step 1: Add the compound of formula I, i.e., 11α, 17β-dihydroxy-18-methylestr-4-en-3-one, to a first organic solvent, and react with an acylating agent in the presence of a base to selectively protect the 17-hydroxyl group to obtain a compound of formula II.
[0023] Step 2: The compound represented by Formula II is reacted with an oxidant in a second organic solvent to oxidize the 11-hydroxyl group of the molecule to obtain a compound represented by Formula III which is an 11-ketone.
[0024] Step 3: The compound represented by Formula III is reacted with a cyclic ketalizing agent in a third organic solvent under acidic catalyst conditions, and the water generated by the reaction is removed by a dehydrating agent / solvent to protect the keto carbonyl group at position 3 to obtain a compound represented by Formula IV.
[0025] Step 4: The compound represented by formula IV is reacted with a Wittig reagent in a fourth organic solvent under alkaline conditions to obtain a compound represented by formula V in which the 11-position methylene group is substituted and the 17-position ester group protection is removed.
[0026] Step 5: The compound represented by formula V is subjected to oxidation reaction in an organic solvent to obtain the target compound represented by formula VI with 17 carbonyl groups, namely 3,3-ethylenedioxy-13-ethyl-11-methylene-5-estren-17-one.
[0027] In the step 1, the acyl substituent of the acylating agent is acetyl, propionyl, pivaloyl, benzoyl, 2-methylbenzoyl, 2,6-dichlorobenzoyl, 2-chlorobenzoyl, preferably benzoyl;
[0028] In the step 1, the first organic solvent is selected from any one solvent or a mixed solvent of dichloromethane, toluene, ethyl acetate, isopropyl acetate, tetrahydrofuran, 2-methyltetrahydrofuran, acetone, acetonitrile, NMP (N-methylpyrrolidone), DMSO (dimethyl sulfoxide), etc., preferably dichloromethane;
[0029] In the step 1, the base is selected from one or more of 4-dimethylaminopyridine, pyridine, 2,6-lutidine, triethylamine, etc., preferably 4-dimethylaminopyridine;
[0030] In the step 1, the molar ratio of the base to the compound represented by formula I is (1.0-5.0):1, preferably 1:1;
[0031] In the step 1, the molar ratio of the acylating agent to the compound represented by formula I is (1.1-2.5):1, preferably 1.1:1;
[0032] The volume ratio of the first organic solvent to the compound represented by formula I is (2-30):1, preferably 20:1;
[0033] In the step 1, the temperature of the acylation reaction is -10°C to 50°C, preferably 15°C to 30°C;
[0034] In the step 1, the acylation reaction time is 0.5 to 12 hours, preferably 6 hours.
[0035] In the step 2, the oxidant is selected from one or more of 2-iodoxybenzoic acid (IBX), chromium trioxide / sulfuric acid, pyridinium chlorochromate (PCC), pyridinium dichromate (PDC), 2,2,6,6-tetramethylpiperidinium oxide / sodium hypochlorite / , sulfur trioxide pyridine / DMSO, acetic anhydride / DMSO, trifluoroacetic anhydride / DMSO, oxalyl chloride / triethylamine / DMSO, etc.; preferably, chromium trioxide / sulfuric acid;
[0036] In step 2, the second organic solvent is one or more of acetone, 4-methyl-2-pentanone, dichloromethane, acetonitrile, DMF (N,N-dimethylformamide), NMP, DMSO, aromatic hydrocarbon solvents, etc., preferably acetone or dichloromethane;
[0037] In the step 2, the molar ratio of the oxidant to the compound represented by formula II is (1.1-5):1, preferably 1.5:1;
[0038] In step 2, the volume ratio of the second organic solvent to the compound represented by formula II is (2-30):1, preferably 15:1;
[0039] In step 2, the temperature of the oxidation reaction is -10°C to 40°C, preferably 0°C to 10°C;
[0040] In step 2, the oxidation reaction time is 0.5 to 12 hours, preferably 5 to 6 hours.
[0041] In the step 3, the cyclic ketalizing agent is selected from ethylene glycol.
[0042] In step 3, the dehydrating agent / solvent is selected from one or more of trimethyl orthoformate, triethyl orthoformate, toluene, cyclohexane, n-heptane, etc., preferably trimethyl orthoformate or triethyl orthoformate;
[0043] In step 3, the acidic catalyst is selected from one or more of p-toluenesulfonic acid, DL-camphorsulfonic acid, sulfuric acid, methanesulfonic acid, etc., preferably p-toluenesulfonic acid;
[0044] In step 3, the third organic solvent is selected from one or more of dichloromethane, toluene, tetrahydrofuran, ethylene glycol dimethyl ether, etc., preferably dichloromethane;
[0045] In the step 3, the molar ratio of the cyclic ketalizing agent to the compound represented by formula III is (1-20):1, preferably 8:1;
[0046] In the step 3, the molar ratio of the acidic catalyst to the compound represented by the formula III is (0.02-1):1, preferably 0.1:1;
[0047] In the step 3, the molar ratio of the dehydrating agent / solvent to the compound represented by formula III is (1.0-10):1, preferably 6:1;
[0048] In step 3, the volume ratio of the third organic solvent to the compound represented by formula III is (1-50):1, preferably 30:1;
[0049] In the step 3, the reaction temperature of the protection is -10°C to 80°C, preferably 20°C to 30°C;
[0050] In the step 3, the reaction time of the protection is 0.5 to 12 hours, preferably 3 hours.
[0051] In step 4, the Wittig reagent is selected from one or more of methyltriphenylphosphine bromide, methyltriphenylphosphine iodide, etc., preferably methyltriphenylphosphine bromide;
[0052] In step 4, the base is selected from one or more of potassium tert-butoxide, sodium tert-butoxide, sodium tert-amylate, sodium hydride, lithium bistrimethylsilylamide, sodium bistrimethylsilylamide, potassium bistrimethylsilylamide, lithium diisopropylamide (LDA), etc., preferably potassium tert-butoxide;
[0053] In the step 4, the fourth organic solvent is selected from any one solvent or a mixed solvent of tetrahydrofuran, toluene, 2-methyltetrahydrofuran, DMSO, NMP, etc., preferably tetrahydrofuran or DMSO;
[0054] In step 4, the molar ratio of the Wittig reagent to the compound represented by formula IV is (1.5-5):1, preferably 4:1;
[0055] In the step 4, the molar ratio of the base to the compound represented by formula IV is (1.5-5):1, preferably 4:1;
[0056] In step 4, the volume ratio of the fourth organic solvent to the compound represented by formula IV is (2-20):1, preferably 10:1;
[0057] In step 4, the reaction temperature of the Wittig is 30°C to 100°C, preferably 60°C to 80°C;
[0058] In step 4, the Wittig reaction time is 1 to 12 hours, preferably 5 to 6 hours.
[0059] In the step 5, the oxidation reagent is one or more of tetrapropylammonium perruthenate / N-methylmorpholine N-oxide, chromium trioxide / sulfuric acid, pyridinium chlorochromate (PCC), pyridinium dichromate (PDC), 2,2,6,6-tetramethylpiperidine oxide / sodium hypochlorite / , sulfur trioxide pyridine / DMSO, acetic anhydride / DMSO, trifluoroacetic anhydride / DMSO, oxalyl chloride / triethylamine / DMSO, etc.;
[0060] In the step 5, the fifth organic solvent is any one of acetone, 4-methyl-2-pentanone, dichloromethane, acetonitrile, DMF, NMP, DMSO, aromatic hydrocarbon solvents, etc., or a mixed solvent thereof, preferably NMP or DMSO;
[0061] In step 5, the molar ratio of the oxidizing agent to the compound represented by formula V is (1.2-5):1, preferably 2.5:1;
[0062] In step 5, the volume ratio of the fifth organic solvent to the compound represented by formula IV is (2-30):1, preferably 15:1;
[0063] In step 5, the temperature of the oxidation reaction is -10°C to 40°C, preferably 25°C to 35°C;
[0064] In step 5, the oxidation reaction time is 1 to 12 hours, preferably 4 to 6 hours.
[0065] The present invention also provides an important intermediate of etonogestrel prepared by the preparation method as described above, wherein the important intermediate of etonogestrel is 3,3-ethylenedioxy-13-ethyl-11-methylene-5-estren-17-one, and its structural formula is as follows:
[0066]
[0067] At present, there is no literature or patent report on the synthesis of etonogestrel using 11α,17β-dihydroxy-18-methylestrone-4-ene-3-one as a raw material. The present invention uses the currently commercially available 11α,17β-dihydroxy-18-methylestrone-4-ene-3-one as a raw material, innovatively protects the 17-hydroxyl group by selectively protecting the 11-hydroxyl group and the 17-hydroxyl group in the presence of the 17-hydroxyl group, and then obtains 3,3-ethylenedioxy-13-ethyl-11-methylene-5-estrone-17-one through oxidation, ketalization, wittig reaction, and oxidation. The route proposed by the present invention not only solves the problems of cost and availability in terms of raw material sources, but also avoids the relatively complex synthesis process of reducing the 17-hydroxyl group first and then oxidizing the hydroxyl group in the process of patent US9422326B2, and does not need to use the dangerous oxidant (2-iodoacylbenzoic acid) mentioned in patent US9422326B2 when oxidizing the 17-hydroxyl group. The method mentioned in the present invention is easy to operate and has high safety, and does not involve hydrogenation and explosive oxidizing agents.
[0068] The beneficial effects of the present invention include: compared with the prior art, the method for synthesizing the important intermediate of etonogestrel of the present invention has cheap and readily available raw materials, avoids the use of low olfactory threshold auxiliary materials, has mild reaction conditions, is simple to operate, has a high overall yield, reduces production costs, and is suitable for industrial production. DETAILED DESCRIPTION
[0069] The present invention is further described in detail with reference to the following specific examples. The process, conditions, experimental methods, etc. for implementing the present invention, except for the contents specifically mentioned below, are all common knowledge and common common sense in the art and are not particularly limited by the present invention.
[0070] The following description of at least one exemplary embodiment is actually only illustrative and is by no means intended to limit the present invention and its application or use. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0071] In all examples shown and discussed herein, any specific values should be interpreted as merely exemplary and not as limiting. Therefore, other examples of the exemplary embodiments may have different values.
[0072] The present invention proposes a method for preparing an important intermediate of etonogestrel (3,3-ethylenedioxy-13-ethyl-11-methylene-5-estren-17-one). The present invention uses commercially available 11α,17β-dihydroxy-18-methylestr-4-ene-3-one as a starting material, and obtains 3,3-ethylenedioxy-13-ethyl-11-methylene-5-estren-17-one through five steps of selective protection, oxidation reaction, protection, Wittig reaction, and oxidation reaction. The entire preparation process has mild reaction conditions, simple and safe processes, and is easy to scale up production, thus providing a safe and efficient technical solution for the preparation of etonogestrel. The present invention has broad application prospects.
[0073] Unless otherwise specified, the test materials used in the examples are all conventional biochemical reagents.
[0074]
[0075] Example 1 Preparation of Compound II-1
[0076]
[0077] In a 2L three-necked glass bottle equipped with a dropping funnel, a thermometer, and a nitrogen protection device, the starting material 11α,17β-dihydroxy-18-methylestr-4-ene-3-one (60.8g, 200mmol) and 4-dimethylaminopyridine (24.4g, 200mmol) were dissolved in 1.2L dichloromethane solution, cooled to 5-10°C, and a dichloromethane (100mL) solution of benzoyl chloride (30.9g, 220mmol) was slowly added dropwise. After the addition, the temperature was raised to 25-30°C, and the reaction was kept warm for 12h. After TLC showed that the conversion of benzoyl chloride was complete, 400mL of water was added to the reaction solution, the liquid was separated, and concentrated to obtain a light yellow solid, which was then purified by slurrying with 240mL of ethyl acetate, filtered and vacuum dried to obtain 63.6g of the white target compound (II-1). The purity was 98.4% and the yield was 78%.
[0078] 1 H NMR(400MHz, CDCl3)δ8.03(d,J=7.7Hz,2H),7.53–7.60(m,1H),7.40–7.49(m,2H),5.84(s,1H),4.99( t,J=8.5Hz,1H),3.68–3.78(m,1H),2.40–2.48(m,8H),1.96–1.02(m,15H).ESI-HRMS:430.9140[M+Na] + .
[0079] Example 2 Preparation of Compound II-2
[0080]
[0081] In a 500mL three-necked glass bottle equipped with a dropping funnel, a thermometer, and a nitrogen protection device, the starting materials 11α, 17β-dihydroxy-18-methylestr-4-ene-3-one (12.16g, 40mmol) and 4-dimethylaminopyridine (4.88g, 40mmol) were dissolved in 240mL of dichloromethane, cooled to 5-10°C, and a dichloromethane (20mL) solution of 2-methylbenzoyl chloride (6.80g, 44mmol) was slowly added dropwise. After the addition, the temperature was raised to 25-30°C and the reaction was kept warm for 12h, the liquid was separated, and the solution was concentrated to obtain a light yellow solid, which was then purified by beating with 50mL of ethyl acetate, filtered, and vacuum dried to obtain 9.28g of the white target compound (II-2). The purity was 98.4% and the yield was 55%. 1 HNMR (400MHz, CDCl3) δ7.93–7.81(m,1H),7.41(d,J=7.6Hz,1H),7.28–7.20(m,2H),5.84(s,1H),4.92(t,J=8 .1Hz,1H),3.83–3.60(m,1H),2.60(s,3H),2.56–2.18(m,9H),2.04–0.92(m,14H).ESI-HRMS:445.2381[M+Na] + .
[0082] Example 3 Preparation of Compound II-3
[0083]
[0084] In a 500mL three-necked glass bottle equipped with a dropping funnel, a thermometer, and a nitrogen protection device, the starting materials 11α,17β-dihydroxy-18-methylestr-4-ene-3-one (12.16g, 40mmol) and 4-dimethylaminopyridine (4.88g, 40mmol) were dissolved in 240mL of dichloromethane, cooled to 5-10°C, and a dichloromethane (25mL) solution of 2-chlorobenzoyl chloride (7.70g, 44mmol) was slowly added dropwise. After the addition, the temperature was raised to 25-30°C and the reaction was kept warm for 12h, the liquid was separated, and the solution was concentrated to obtain a light yellow solid, which was then purified by beating with 50mL of ethyl acetate, filtered, and dried in vacuo to obtain 11.5g of the white target compound (II-3). The purity was 98.4% and the yield was 65%. 1H NMR (400MHz, CDCl3) δ7.80–7.73(m,1H),7.49–7.32(m,2H),7.35–7.29(m,1H),5.83(s,1H),4.92(t, J=8.5Hz,1H),3.77–3.67(m,1H),2.54–2.19(m,8H),1.98–0.95(m,15H).ESI-HRMS:465.1809[M+Na] + .
[0085] Example 4 Preparation of Compound III-1
[0086]
[0087] In a 1000mL three-necked glass bottle with a dropping funnel, a thermometer, and a nitrogen protection device, the substrate II-1 (16.32g, 40mmol) was dissolved in 250mL of acetone, cooled to 0-10°C, and Jones reagent (2.5M, 20mL) solution was slowly added dropwise. After the addition was completed, the temperature was raised to 25-30°C for 1-2h of incubation. After TLC showed that the raw material conversion was complete, 15mL of isopropanol was slowly added dropwise to quench the reaction. After the color of the reaction solution changed from orange-red to a green clear solution, 250mL of purified water was added to precipitate a large amount of white solid, and the temperature was kept at <10°C for 1h. Filter, wash the filter cake with purified water until the pH of the effluent is 6-7, collect the filter cake, and vacuum dry to obtain 13.31g of compound (III-1), with a purity of 99% and a yield of 82%. 1 HNMR (400MHz, CDCl3) δ8.02(d,J=7.8Hz,2H),7.57(t,J=7.4Hz,1H),7.45(t,J=7.8Hz,2H),5.88(s,1H),5.18(t,J=8.6 Hz,1H),2.90(d,J=12.0Hz,1H),2.74-2.65(m,1H),2.58–2.17(m,7H),2.06–1.01(m,14H).ESI-HRMS:429.2037[M+Na] + .
[0088] Example 5 Preparation of Compound III-2
[0089]
[0090] In a 500mL three-necked glass bottle with a dropping funnel, a thermometer, and a nitrogen protection device, the substrate II-2 (9.28g, 22mmol) was dissolved in 150mL of acetone, cooled to 0-10°C, and Jones reagent (chromium trioxide / sulfuric acid) (2.5M, 11mL) solution was slowly added dropwise. After the addition was completed, the temperature was raised to 25-30°C for 1-2h of incubation. After TLC showed that the raw material conversion was complete, 5mL of isopropanol was slowly added dropwise to quench the reaction. After the color of the reaction solution changed from orange-red to a green clear solution, 150mL of purified water was added to precipitate a large amount of white solid, and the temperature was kept at <10°C for 1h. Filter, wash the filter cake with purified water until the pH of the effluent is 6-7, collect the filter cake, and vacuum dry to obtain 7.02g of compound (III-2), with a purity of 98% and a yield of 76%. 1 HNMR(400MHz, CDCl3)δ7.86(d,J=7.7Hz,1H),7.41(t,J=7.7Hz,1H),7.29-7.20(m,2H),5.88(s,1H),5.13(t,J=8.7Hz,1 H),2.91(dd,J=11.8,2.8Hz,1H),2.68(d,J=12.3Hz,1H),2.59(d,J=2.6Hz,3H),2.56–2.16(m,7H),2.04–0.99(m,14H).
[0091] ESI-HRMS:443.2190[M+Na] + .
[0092] Example 6 Preparation of Compound III-3
[0093]
[0094] In a 500mL three-necked glass bottle with a dropping funnel, a thermometer, and a nitrogen protection device, the substrate II-3 (11.50g, 26mmol) was dissolved in 170mL of acetone, cooled to 0-10°C, and Jones reagent (2.5M, 13mL) solution was slowly added dropwise. After the addition was completed, the temperature was raised to 25-30°C for 1-2h of incubation. After TLC showed that the raw material conversion was complete, 5mL of isopropanol was slowly added dropwise to quench the reaction. After the color of the reaction solution changed from orange-red to a green clear solution, 170mL of purified water was added to precipitate a large amount of white solid, and the temperature was kept at <10°C for 1h. Filter, wash the filter cake with purified water until the pH of the effluent is 6-7, collect the filter cake, and vacuum dry to obtain 9.7g of compound (III-3), with a purity of 99% and a yield of 85%. 1HNMR(400MHz, CDCl3)δ7.77(d,J=7.7Hz,1H),7.50–7.39(m,2H),7.36–7.28(m,1H),5.88(s,1H),5.14(t,J=8.6Hz,1 H),2.94(d,J=12.0Hz,1H),2.77–2.18(m,8H),2.05–1.17(m,11H),1.02(t,J=7.4Hz,3H).ESI-HRMS:463.1663[M+Na] + .
[0095] Example 7 Preparation of Compound IV-1
[0096]
[0097] Under nitrogen protection, compound III-1 (13 g, 32 mmol) was dissolved in 195 mL of dichloromethane, and 13 g of ethylene glycol, 13 g of triethyl orthoformate, and 1.3 g of p-toluenesulfonic acid were added in sequence. After the addition was completed, the system was stirred at 20-25 ° C. After TLC showed that the conversion of the raw materials was complete, 1.5 mL of triethylamine and 200 mL of 5% sodium bicarbonate aqueous solution were added to the reaction solution, and the mixture was stirred for 30 minutes and allowed to stand for separation. The aqueous phase was discarded, and the dichloromethane layer was washed with 200 mL of 5% sodium chloride aqueous solution, and allowed to stand for separation. The aqueous phase was discarded, and the dichloromethane layer was concentrated to dryness to obtain 11.81 g of a white solid (IV-1) with a purity of 97% and a yield of 82%. 1 H NMR(400MHz, CDCl3) δ8.02(d,J=7.7Hz,2H),7.60–7.52(m,1H),7.48–7.41(m,2H),5.47(d,J=5.9Hz,1H),5. 21–5.12(m,1H),4.01–3.89(m,4H),2.90(d,J=12.5Hz,1H),2.58–0.90(m,22H).ESI-HRMS:473.2300[M+Na] + .
[0098] Example 8 Preparation of Compound IV-2
[0099]
[0100] Under nitrogen protection, compound III-2 (7g, 16.7mmol) was dissolved in 105mL dichloromethane, and ethylene glycol 7g, triethyl orthoformate 7g, and p-toluenesulfonic acid 0.7g were added in sequence. After the addition was completed, the system was stirred at 20-25°C for reaction. After TLC showed that the conversion of the raw materials was complete, 0.8mL triethylamine and 100mL 5% sodium bicarbonate solution were added to the reaction solution, and the mixture was stirred for 30 minutes and allowed to stand for separation. The aqueous phase was discarded, and the dichloromethane layer was washed with 100mL 5% sodium chloride aqueous solution, allowed to stand for separation, and the aqueous phase was discarded. The dichloromethane layer was concentrated to dryness to obtain 6.1g of yellow-white solid (IV-2) with a purity of 98% and a yield of 79%. 1 H NMR(400MHz, CDCl3)δ7.86(d,J=7.7Hz,1H),7.40(t,J=7.4Hz,1H),7.30–7.20(m,2H),5.47(d,J=6.0Hz,1H),5.17–5 .07(m,1H),4.05–3.86(m,4H),2.91(d,J=12.5Hz,1H),2.59(s,3H),2.50–0.90(m,22H).ESI-HRMS:487.2647[M+Na] + .
[0101] Example 9 Preparation of Compound IV-3
[0102]
[0103] Under nitrogen protection, compound III-3 (9.7 g, 22 mmol) was dissolved in 150 mL of dichloromethane, and 9 g of ethylene glycol, 9 g of triethyl orthoformate, and 1.0 g of p-toluenesulfonic acid were added in sequence. After the addition was completed, the system was stirred at 20-25 ° C. After TLC showed that the conversion of the raw materials was complete, 1.0 mL of triethylamine and 150 mL of 5% sodium bicarbonate solution were added to the reaction solution, and the mixture was stirred for 30 minutes and allowed to stand for separation. The aqueous phase was discarded, and the dichloromethane layer was washed with 150 mL of 5% sodium chloride aqueous solution, and the mixture was allowed to stand for separation. The aqueous phase was discarded, and the dichloromethane layer was concentrated to dryness to obtain 9.05 g of a white solid (IV-3) with a purity of 98% and a yield of 85%. 1 H NMR(400MHz, CDCl3)δ7.76(d,J=7.7Hz,1H),7.49–7.39(m,2H),7.38–7.25(m,1H),5.47(d,J=5.8Hz,1H),5.1 3(t,J=8.6Hz,1H),4.12–3.84(m,4H),2.93(d,J=12.4Hz,1H),2.60–0.90(m,22H).ESI-HRMS:507.1933[M+Na] + .
[0104] Example 10 Preparation of Compound V
[0105]
[0106] Under nitrogen protection, methyl triphenylphosphonium bromide (5.35 g, 15 mmol) was dispersed in 20 mL DMSO, followed by the addition of sodium hydride (600 mg, 15 mmol). After nitrogen replacement, the mixture was stirred at room temperature for 30 minutes, followed by the addition of a DMSO (5 mL) solution of IV-1 (2.25 g, 5 mmol). After the addition, the system was stirred at 75-80 ° C for 6 h. After TLC showed that the raw material conversion was complete, 60 mL of water was added to the reaction solution, and a large amount of white solid was precipitated. The solid was filtered and dried in vacuo to obtain 1.43 g of the target compound (V) with a purity of 98.6% and a yield of 83%. 1 H NMR(400MHz, CDCl3)5.50(d,J=5.8Hz,1H),4.97(s,1H),4.80(s,1H),4.01–3.96(m,4H),3.7 4(t,J=8.6Hz,1H),2.77(d,J=12.5Hz,1H),2.33-1.0ppm(m,23H).ESI-HRMS:376.2302[M+Na] + .
[0107] Example 11 Preparation of Compound V
[0108]
[0109] Under nitrogen protection, methyl triphenylphosphonium bromide (5.35 g, 15 mmol) was dispersed in 20 mL DMSO, followed by the addition of sodium hydrogen (600 mg, 15 mmol). After nitrogen replacement, the mixture was stirred at room temperature for 30 minutes, followed by the addition of a DMSO (5 mL) solution of IV-2 (2.32 g, 5 mmol). After the addition, the system was stirred at 75-80 ° C for 6 h. After TLC showed that the raw material conversion was complete, 60 mL of water was added to the reaction solution, and a large amount of white solid was precipitated. The solid was filtered and dried in vacuo to obtain 1.38 g of the target compound (V) with a purity of 98.2% and a yield of 80%.
[0110] Example 12 Preparation of Compound V
[0111]
[0112] Under nitrogen protection, methyl triphenylphosphonium bromide (5.35 g, 15 mmol) was dispersed in 20 mL DMSO, followed by the addition of sodium hydrogen (600 mg, 15 mmol). After nitrogen replacement, the mixture was stirred at room temperature for 30 minutes, followed by the addition of a DMSO (5 mL) solution of IV-3 (2.42 g, 5 mmol). After the addition, the system was stirred at 75-80 ° C for 6 h. After TLC showed that the raw material conversion was complete, 60 mL of water was added to the reaction solution, and a large amount of white solid was precipitated. The solid was filtered and dried in vacuo to obtain 1.32 g of the target compound (V) with a purity of 98% and a yield of 77%.
[0113] Example 13 Preparation of Compound IV-4
[0114] The synthesis of compound II-4 represented by the general formula can refer to Example 1 of the present invention, the synthesis of compound III-4 represented by the general formula can refer to Example 2 of the present invention, and the synthesis of compound IV-4 represented by the general formula can refer to the method in Example 3 of the present invention.
[0115]
[0116] Under nitrogen protection, compound V (3.44 g, 10 mmol) was dissolved in 20 mL DMSO, 50 mg of tetrapropylammonium perruthenate (TPAP) was added, and N-methylmorpholine-N-oxide (4.10 g, 35 mmol) was slowly added dropwise. After the addition was completed, the reaction was stirred at 25-30°C for 3 h. After TLC showed that the raw material conversion was complete, 40 mL of water was added to the reaction solution, and a large amount of white solid was precipitated. After filtration, the filter cake was washed with 20 mL of dichloromethane solvent, and the dichloromethane solution was washed with 10 mL of 5% HCl aqueous solution, 5% sodium bicarbonate solution, and 5% sodium chloride solution in sequence. Subsequently, it was dried over anhydrous sodium sulfate and concentrated to dryness to obtain 3.07 g of the target compound VI as a white solid with a purity of 99% and a yield of 90%.
[0117] Unless otherwise defined, all technical and scientific terms used in the present invention have the same meaning as those commonly understood by those skilled in the art of the present invention. The terms used in the specification of the present invention are only for the purpose of describing specific embodiments and are not intended to limit the present invention.
[0118] As used in the present invention, the term "comprising" is an open expression, that is, including the contents specified in the present invention but not excluding other contents.
[0119] As used in the present invention, the term "and / or" includes any and all combinations of one or more of the related listed items. The technical features of the above-mentioned embodiments can be combined arbitrarily. In order to make the description concise, all possible combinations of the technical features in the above-mentioned embodiments are not described. However, as long as there is no contradiction in the combination of these technical features, they should be considered to be within the scope of this specification. It should be pointed out that for ordinary technicians in this field, several variations and improvements can be made without departing from the concept of the present invention, which all belong to the protection scope of the present invention. Therefore, the protection scope of the patent of the present invention shall be based on the attached claims, and the description can be used to interpret the content of the claims.
Claims
1. A method for preparing an etonogestrel intermediate, characterized in that: The preparation method uses the commercially available compound 11α,17β-dihydroxy-18-methylestr-4-ene-3-one shown in formula I as a starting material, and obtains the important intermediate of etonogestrel, i.e., the compound 3,3-ethylenedioxy-13-ethyl-11-methylene-5-estrene-17-one shown in formula VI, through selective protection, oxidation reaction, protection, Wittig reaction, and oxidation reaction; the reaction process of the preparation method is shown in reaction formula (I): Wherein, R is selected from benzoyl, 2-substituted benzoyl, 2,6-disubstituted benzoyl, and alkanoyl.
2. The preparation method according to claim 1, characterized in that The R is shown in the following formula: The substituent R' is selected from H, alkyl, and halogen.
3. The preparation method according to claim 1, characterized in that: The preparation method comprises the following steps: Step 1: Add the compound 11α,17β-dihydroxy-18-methylestr-4-en-3-one represented by formula I to a first organic solvent, and react with an acylating agent in the presence of a base to selectively protect the 17-hydroxyl group to obtain a compound represented by formula II; Step 2: The compound represented by Formula II is reacted with an oxidant in a second organic solvent to oxidize the 11-hydroxyl group to obtain a compound represented by Formula III which is an 11-ketone; Step 3: The compound represented by Formula III is reacted with a cyclic ketalizing agent in a third organic solvent under an acidic catalyst condition, and the water generated by the reaction is removed by a dehydrating agent / solvent to protect the keto carbonyl group at position 3 to obtain a compound represented by Formula IV; Step 4: The compound represented by Formula IV is reacted with a Wittig reagent in a fourth organic solvent under alkaline conditions to obtain a compound represented by Formula V by methyleneization at position 11 and deprotection of the ester group at position 17; Step 5: The compound represented by Formula V is subjected to an oxidation reaction in a fifth organic solvent to obtain the target compound represented by 17-carbonyl Formula VI, namely 3,3-ethylenedioxy-13-ethyl-11-methylene-5-estren-17-one.
4. The preparation method according to claim 3, characterized in that: In step 1: The acyl substituent of the acylating agent is benzoyl, 2-methylbenzoyl, 2,6-dichlorobenzoyl, 2-chlorobenzoyl, acetyl, propionyl, pivaloyl; and / or, The first organic solvent is selected from any one solvent or a mixed solvent of dichloromethane, toluene, ethyl acetate, isopropyl acetate, tetrahydrofuran, 2-methyltetrahydrofuran, acetone, acetonitrile, NMP, and DMSO; and / or, The base is selected from one or more of 4-dimethylaminopyridine, pyridine, 2,6-lutidine, and triethylamine; and / or, The molar ratio of the base to the compound represented by the formula I is (1.0-5.0):1; and / or, The molar ratio of the acylating agent to the compound represented by formula I is (1.1-2.5):1; and / or, The volume ratio of the first organic solvent to the compound represented by formula I is (2-30):1; and / or, The temperature of the acylation reaction is -10°C to 50°C; and / or, The acylation reaction time is 0.5 to 12 hours.
5. The preparation method according to claim 3, characterized in that: In the step 2, The oxidant is selected from one or more of 2-iodoxybenzoic acid (IBX), chromium trioxide / sulfuric acid, pyridinium chlorochromate (PCC), pyridinium dichromate (PDC), 2,2,6,6-tetramethylpiperidinium oxide / sodium hypochlorite / , sulfur trioxide pyridine / DMSO, acetic anhydride / DMSO, trifluoroacetic anhydride / DMSO, oxalyl chloride / triethylamine / DMSO; and / or, The second organic solvent is one or more of acetone, 4-methyl-2-pentanone, dichloromethane, acetonitrile, DMF, NMP, DMSO, and aromatic hydrocarbon solvents; and / or, The molar ratio of the oxidant to the compound represented by formula II is (1.1-5.0):1; and / or, The volume ratio of the second organic solvent to the compound represented by formula II is (2-30):1; and / or, The temperature of the oxidation reaction is -10°C to 40°C; and / or, The oxidation reaction time is 0.5 to 12 hours.
6. The preparation method according to claim 3, characterized in that: In step 3: The cyclic ketalizing agent is selected from ethylene glycol; and / or, The dehydrating agent / solvent is selected from one or more of trimethyl orthoformate, triethyl orthoformate, toluene, cyclohexane, and n-heptane; and / or, The acidic catalyst is selected from one or more of p-toluenesulfonic acid, DL-camphorsulfonic acid, sulfuric acid, and methanesulfonic acid; and / or, The third organic solvent is selected from one or more of dichloromethane, toluene, tetrahydrofuran, and ethylene glycol dimethyl ether; The molar ratio of the cyclic ketalizing agent to the compound represented by the formula III is (1.0-20.0):1; and / or, The molar ratio of the acidic catalyst to the compound represented by the formula III is (0.02-1):1; and / or, The molar ratio of the dehydrating agent / solvent to the compound represented by the formula III is (1.0-10):1; and / or, The volume ratio of the third organic solvent to the compound represented by the formula III is (1-50):1; and / or, The reaction temperature of the protection is -10°C to 80°C; and / or, The reaction time of the protection is 0.5 to 12 hours.
7. The preparation method according to claim 3, characterized in that: In step 4: The Wittig reagent is selected from one or both of methyltriphenylphosphine bromide and methyltriphenylphosphine iodide; and / or, The base is selected from one or more of potassium tert-butoxide, sodium tert-butoxide, sodium tert-amylate, sodium hydride, lithium bistrimethylsilylamide, sodium bistrimethylsilylamide, potassium bistrimethylsilylamide, and lithium diisopropylamide; and / or, The fourth organic solvent is selected from any one solvent or a mixed solvent of tetrahydrofuran, toluene, 2-methyltetrahydrofuran, DMSO, and NMP; and / or, The molar ratio of the Wittig reagent to the compound represented by the formula IV is (1.5-5.0):1; and / or, The molar ratio of the base to the compound represented by formula IV is (1.5-5.0):1; and / or, The volume ratio of the fourth organic solvent to the compound represented by formula IV is (2-20):1; and / or, The Wittig reaction temperature is 30°C to 100°C; and / or, The Wittig reaction time is 1 to 12 hours.
8. The preparation method according to claim 3, characterized in that: In step 5: The oxidation reagent is one or more of tetrapropylammonium perruthenate / N-methylmorpholine-N-oxide, chromium trioxide / sulfuric acid, pyridinium chlorochromate (PCC), pyridinium dichromate (PDC), 2,2,6,6-tetramethylpiperidine oxide / sodium hypochlorite / , sulfur trioxide pyridine / DMSO, acetic anhydride / DMSO, trifluoroacetic anhydride / DMSO, oxalyl chloride / triethylamine / DMSO; and / or, The fifth organic solvent is any one of acetone, 4-methyl-2-pentanone, dichloromethane, acetonitrile, DMF, NMP, DMSO, and aromatic hydrocarbon solvents, or a mixed solvent thereof; and / or, The molar ratio of the oxidizing agent to the compound represented by the formula V is (1.2-5):1; and / or, The volume ratio of the fifth organic solvent to the compound represented by formula V is (2-30):1; and / or, The temperature of the oxidation reaction is -10°C to 40°C; and / or, The oxidation reaction time is 1 to 12 hours.
9. The etonogestrel intermediate prepared by the method according to any one of claims 1 to 8.
Citation Information
Patent Citations
Preparation method of desogestrel, etogestrel and key intermediates thereof
CN117126221A
Process for preparing 11-methylene-18-methyl-estr-4-en-3, 17-dione, useful as intermediate compound for the synthesis of molecules having pharmacological activity
US9422326B2
Methods for the preparation of etonogestrel and desogestrel
WO2013071210A1
Process and new intermediates for the preparation of 11-methylene steroids
WO2017149091A1
